Dennis Dean - Airsculpt Technologies Chief Officer
| AIRS Stock | USD 4.54 0.07 1.57% |
Insider
Dennis Dean is Chief Officer of Airsculpt Technologies
| Age | 52 |
| Phone | 786 709 9690 |
| Web | https://www.airsculpt.com |
Dennis Dean Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dennis Dean against Airsculpt Technologies stock is an integral part of due diligence when investing in Airsculpt Technologies. Dennis Dean insider activity provides valuable insight into whether Airsculpt Technologies is net buyers or sellers over its current business cycle. Note, Airsculpt Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell Airsculpt Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dennis Dean over three months ago Disposition of 24510 shares by Dennis Dean of Airsculpt Technologies at 6.5447 subject to Rule 16b-3 | ||
Dennis Dean over a year ago Acquisition by Dennis Dean of 42230 shares of Airsculpt Technologies subject to Rule 16b-3 |
Airsculpt Technologies Management Efficiency
The company has return on total asset (ROA) of 0.0112 % which means that it generated a profit of $0.0112 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0935) %, meaning that it created substantial loss on money invested by shareholders. Airsculpt Technologies' management efficiency ratios could be used to measure how well Airsculpt Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Patrick Cunningham | Aveanna Healthcare Holdings | 69 | |
| John Gochnour | Pennant Group | 41 | |
| Philip Reger | Oncology Institute | N/A | |
| David CPA | Aveanna Healthcare Holdings | 52 | |
| Adam Holton | Amedisys | 53 | |
| Gregory Carmichael | Encompass Health Corp | 59 | |
| Denise Bohnert | Amedisys | 47 | |
| Dan Peoples | Enhabit | N/A | |
| Tanya Marion | Enhabit | 50 | |
| Kevin Connor | Encompass Health Corp | 53 | |
| Janet Britt | Amedisys | N/A | |
| Anthony Hernandez | Encompass Health Corp | 59 | |
| MD JD | Acadia Healthcare | N/A | |
| Maria Lozzano | InnovAge Holding Corp | 44 | |
| Patricia Maryland | Encompass Health Corp | 67 | |
| Mark Miller | Encompass Health Corp | N/A | |
| Matthew Peterson | Universal Health Services | 55 | |
| Ryan Kubota | InnovAge Holding Corp | N/A | |
| Robert Radics | Aveanna Healthcare Holdings | N/A | |
| MD MBA | Oncology Institute | 47 | |
| PT MBA | Enhabit | N/A | |
Management Performance
| Return On Equity | -0.0935 | ||||
| Return On Asset | 0.0112 |
Airsculpt Technologies Leadership Team
Elected by the shareholders, the Airsculpt Technologies' board of directors comprises two types of representatives: Airsculpt Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Airsculpt. The board's role is to monitor Airsculpt Technologies' management team and ensure that shareholders' interests are well served. Airsculpt Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Airsculpt Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dennis Dean, Chief Officer | ||
| Stephanie Greene, Chief Officer | ||
| Philip Bodie, Chief Officer | ||
| Aaron MD, Founder Chairman | ||
| Liraz Isaac, Head People | ||
| Todd Magazine, President CEO | ||
| Dennis CPA, Chief Officer | ||
| Ronald Zelhof, COO Pres | ||
| Yogesh Jashnani, CEO Director |
Airsculpt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Airsculpt Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0935 | ||||
| Return On Asset | 0.0112 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 357.27 M | ||||
| Shares Outstanding | 57.88 M | ||||
| Shares Owned By Insiders | 27.02 % | ||||
| Shares Owned By Institutions | 74.00 % | ||||
| Number Of Shares Shorted | 3.06 M | ||||
| Price To Earning | 143.17 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Airsculpt Stock Analysis
When running Airsculpt Technologies' price analysis, check to measure Airsculpt Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Airsculpt Technologies is operating at the current time. Most of Airsculpt Technologies' value examination focuses on studying past and present price action to predict the probability of Airsculpt Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Airsculpt Technologies' price. Additionally, you may evaluate how the addition of Airsculpt Technologies to your portfolios can decrease your overall portfolio volatility.